ADEL,inc. develops novel Alzheimer's disease therapeutics & diagnostics.
Phone: +82 2-3010-4191
Investors 1
| Date | Name | Website |
| 09.04.2026 | MINT Ventu... | mintventur... |
Mentions in press and media 3
| Date | Title | Description |
| 23.02.2024 | Oscotec/ADEL Initiates First-in-Human Dosing in Ph1 of Anti-MTBR Tau Antibody ADEL-Y01 In Alzheimer's Disease | PANGYO, South Korea, Feb. 23, 2024 /PRNewswire/ -- Oscotec Inc. and ADEL Inc. announced the dosing of the first healthy participant in its first-in-human study of ADEL-Y01 for the treatment of Alzheimer's disease (AD). Oscotec and ADEL are ... |
| 14.09.2023 | Oscotec/ADEL Announce FDA Clearance of IND Application of ADEL-Y01 for the Treatment of Alzheimer's Disease | PANGYO, South Korea, Sept. 14, 2023 /PRNewswire/ -- Oscotec Inc. and ADEL Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application of ADEL-Y01 for the treatment of Alzheimer'... |
| - | ADEL | “We dream of a world without dementia. Alzhheimer's Disease Experts Lab, ADEL,Inc.” |